DE69025946T2 - Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma - Google Patents

Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma

Info

Publication number
DE69025946T2
DE69025946T2 DE69025946T DE69025946T DE69025946T2 DE 69025946 T2 DE69025946 T2 DE 69025946T2 DE 69025946 T DE69025946 T DE 69025946T DE 69025946 T DE69025946 T DE 69025946T DE 69025946 T2 DE69025946 T2 DE 69025946T2
Authority
DE
Germany
Prior art keywords
tumor
receptor
alterations
rearrangements
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69025946T
Other languages
English (en)
Other versions
DE69025946D1 (de
Inventor
Bert Vogelstein
Darell Bigner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Duke University
Original Assignee
Johns Hopkins University
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Duke University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69025946D1 publication Critical patent/DE69025946D1/de
Publication of DE69025946T2 publication Critical patent/DE69025946T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
DE69025946T 1989-09-08 1990-08-15 Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma Expired - Lifetime DE69025946T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40422689A 1989-09-08 1989-09-08
US53141090A 1990-06-01 1990-06-01
PCT/US1990/004489 WO1991003489A1 (en) 1989-09-08 1990-08-15 Structural alterations of the egf receptor gene in human gliomas

Publications (2)

Publication Number Publication Date
DE69025946D1 DE69025946D1 (de) 1996-04-18
DE69025946T2 true DE69025946T2 (de) 1996-10-17

Family

ID=27018564

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69025946T Expired - Lifetime DE69025946T2 (de) 1989-09-08 1990-08-15 Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma

Country Status (8)

Country Link
US (4) US5212290A (de)
EP (1) EP0491007B1 (de)
JP (1) JP2975679B2 (de)
AT (1) ATE135373T1 (de)
AU (1) AU639726B2 (de)
CA (1) CA2066428C (de)
DE (1) DE69025946T2 (de)
WO (1) WO1991003489A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628986B2 (en) 2003-06-27 2009-12-08 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981725A (en) * 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
DE4129533A1 (de) * 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
DK0659439T3 (da) 1993-12-24 2002-01-14 Merck Patent Gmbh Immunkonjugater
EP0796277B1 (de) * 1994-11-28 2004-03-24 Thomas Jefferson University Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US6667156B2 (en) * 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
HU226742B1 (en) 1999-06-25 2009-08-28 Genentech Inc Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
US6790614B1 (en) * 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
EP1276771A4 (de) * 2000-03-10 2003-06-04 Thomas Jefferson Univarsity Empfindlicher nachweis von egfr-mutanten und wildtyp durch spezifische elisa-nachweise in jeglicher biologischer probe
AUPQ841800A0 (en) 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) * 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
WO2003101474A1 (en) * 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
JP5069843B2 (ja) 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP2423331B1 (de) 2004-03-31 2019-05-08 The General Hospital Corporation Verfahren zur Bestimmung des Ansprechens von Krebs auf den epidermalen Wachstumsfaktorrezeptor gerichtete Behandlungen
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20190110637A (ko) 2005-01-21 2019-09-30 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
RU2404806C2 (ru) 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
JP2008535477A (ja) * 2005-02-24 2008-09-04 アムジエン・インコーポレーテツド 上皮成長因子受容体変異
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
GB2424886A (en) 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
EP2010911A4 (de) * 2006-03-31 2009-05-13 Massachusetts Inst Technology Behandlung von egf-rezeptormutanten exprimierenden tumoren
ATE522625T1 (de) 2006-09-12 2011-09-15 Genentech Inc Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
WO2008091701A2 (en) 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
US9340601B2 (en) * 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
JP2011516078A (ja) * 2008-04-10 2011-05-26 セル・シグナリング・テクノロジー・インコーポレイテツド 癌におけるｅｇｆｒ突然変異を検出する組成物および方法
US8227439B2 (en) 2008-05-15 2012-07-24 Morphotek, Inc. Treatment of metastatic tumors
TW201544123A (zh) 2009-03-20 2015-12-01 Genentech Inc 抗-ｈｅｒ抗體
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
JP6007105B2 (ja) 2009-12-22 2016-10-12 セルデックス・セラピューティクス・インコーポレイテッド ワクチン組成物
CA2781578A1 (en) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
RS56231B1 (sr) 2010-02-04 2017-11-30 Morphotek Inc Polipeptidi i konjugati hlorotoksina i njihove upotrebe
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
MX2012010265A (es) 2010-03-17 2012-10-01 Hoffmann La Roche Compuestos de imidazopiridina, composiciones y metodos de uso.
JP2013528787A (ja) 2010-04-16 2013-07-11 ジェネンテック， インコーポレイテッド Ｐｉ３ｋ／ａｋｔキナーゼ経路インヒビターの効果の予測バイオマーカーとしてのｆｏｘ０３ａ
JP2013532126A (ja) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
DK2612151T3 (en) 2010-08-31 2017-10-02 Genentech Inc BIOMARKETS AND METHODS OF TREATMENT
RU2013114352A (ru) 2010-09-15 2014-10-20 Ф. Хоффманн-Ля Рош Аг Азабензотиазолы, композиции и способы применения
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
MX2013005445A (es) 2010-11-19 2013-07-29 Hoffmann La Roche Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
JP2014527397A (ja) 2011-06-20 2014-10-16 トラスラショナル、キャンサー、ドラッグス、ファーマ、ソシエダッド、リミターダＴｒａｓｌａｔｉｏｎａｌ Ｃａｎｃｅｒ Ｄｒｕｇｓ Ｐｈａｒｍａ， Ｓ．Ｌ． 癌患者の化学療法に対する臨床応答を予測する方法
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
CA2843499A1 (en) 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag Indazole compounds, compositions and methods of use
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
BR112014006643A2 (pt) 2011-09-20 2017-04-04 Hoffmann La Roche compostos de imidazopiridina, composições e métodos de uso dos mesmos
AP2014007638A0 (en) 2011-11-16 2014-05-31 Amgen Inc Methods of treating epidermal growth factor deletion mutant VIII related disorders
SG11201402343SA (en) 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
WO2013174432A1 (en) 2012-05-24 2013-11-28 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
CN104780938A (zh) 2012-08-02 2015-07-15 小利兰·斯坦福大学托管委员会 用于肿瘤治疗的基于EGFRvIII序列的肽疫苗
WO2014063205A1 (en) 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
EA031184B1 (ru) 2012-11-21 2018-11-30 Янссен Байотек, Инк. БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
WO2014093406A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
EP3626741A1 (de) 2013-02-20 2020-03-25 The Trustees Of The University Of Pennsylvania Behandlung von krebs mit humanisiertem chimärem anti-egfrviii-antigenrezeptor
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
CA2903480A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
BR112015022604A2 (pt) 2013-03-14 2017-10-24 Genentech Inc usos de um modulador de modificador de cromatina e um antagonista de egfr
EP2968537A1 (de) 2013-03-15 2016-01-20 Genentech, Inc. Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
JP6242484B2 (ja) 2013-07-09 2017-12-06 デューク ユニバーシティー 特定の改善されたヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子
RU2016112568A (ru) 2013-09-05 2017-10-06 Дженентек, Инк. Антипролиферативные соединения
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
TW201605857A (zh) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
KR20160070136A (ko) 2013-10-18 2016-06-17 제넨테크, 인크. 항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
NZ720515A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EA035809B1 (ru) 2014-03-11 2020-08-14 Регенерон Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
KR20220025946A (ko) 2014-03-21 2022-03-03 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
MA39776A (fr) 2014-03-24 2017-02-01 Hoffmann La Roche Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
MA51552A (fr) 2014-03-31 2021-03-24 Hoffmann La Roche Anticorps anti-ox40 et procédés d'utilisation
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
US9493764B2 (en) * 2014-04-22 2016-11-15 Korea Institute Of Science And Technology Hybrid electronic sheets
WO2016036873A1 (en) 2014-09-05 2016-03-10 Genentech, Inc. Therapeutic compounds and uses thereof
EP3193866A1 (de) 2014-09-19 2017-07-26 Genentech, Inc. Verwendung von cbp/ep300- und bet-inhibitoren zur behandlung von krebs
CN107912040B (zh) 2014-10-10 2021-04-06 基因泰克公司 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
CN107109484B (zh) 2014-11-03 2021-12-14 豪夫迈·罗氏有限公司 用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
CN106796235B (zh) 2014-11-03 2021-01-29 豪夫迈·罗氏有限公司 用于检测t细胞免疫子集的测定法及其使用方法
CN107073126A (zh) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 包含ox40结合激动剂和tigit抑制剂的组合疗法
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3218376B1 (de) 2014-11-10 2019-12-25 Genentech, Inc. Bromodomaininhibitoren und deren verwendung
BR112017010198A2 (pt) 2014-11-17 2017-12-26 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
JP2018508183A (ja) 2014-12-23 2018-03-29 ジェネンテック， インコーポレイテッド 化学療法耐性癌を治療及び診断する組成物及び方法
JP2018503373A (ja) 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
CN107406418B (zh) 2015-01-09 2021-10-29 基因泰克公司 4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
JP6659703B2 (ja) 2015-01-09 2020-03-04 ジェネンテック， インコーポレイテッド ピリダジノン誘導体および癌の処置におけるそれらの使用
JP6855379B2 (ja) 2015-01-09 2021-04-07 ジェネンテック， インコーポレイテッド 癌の処置のためのヒストンデメチラーゼｋｄｍ２ｂのインヒビターとしての（ピペリジン−３−イル）（ナフタレン−２−イル）メタノン誘導体および関連化合物
WO2016123391A1 (en) 2015-01-29 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
CN107438593B (zh) 2015-01-30 2020-10-30 基因泰克公司 治疗化合物及其用途
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
JP7048319B2 (ja) 2015-05-12 2022-04-05 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
JP7144935B2 (ja) 2015-05-29 2022-09-30 ジェネンテック， インコーポレイテッド 癌のための治療方法及び診断方法
MX2017014740A (es) 2015-06-08 2018-08-15 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
EP3310815A1 (de) 2015-06-17 2018-04-25 F. Hoffmann-La Roche AG Verfahren zur behandlung von lokal fortgeschrittenen oder metastatischen brustkrebsen unter verwendung von pd-1-achse-bindenden antagonisten und taxanen
EP3341376B1 (de) 2015-08-26 2020-12-23 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Kondensierte tricyclische verbindungen als hemmer von protein kinase
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
AU2016369528B2 (en) 2015-12-16 2021-04-22 Genentech, Inc. Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109311995A (zh) 2016-03-29 2019-02-05 台湾浩鼎生技股份有限公司 抗体、药物组合物和方法
US20170319688A1 (en) 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
KR20190003958A (ko) 2016-04-15 2019-01-10 제넨테크, 인크. 암의 치료 및 모니터링 방법
BR112018071683A2 (pt) 2016-04-22 2019-02-19 Obi Pharma, Inc. método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
EP3454863A1 (de) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombinationstherapien zur behandlung von krebs
CN109476663B (zh) 2016-05-24 2021-11-09 基因泰克公司 用于治疗癌症的吡唑并吡啶衍生物
JP7160688B2 (ja) 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
US20200129519A1 (en) 2016-06-08 2020-04-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018013918A2 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
KR20190036551A (ko) 2016-08-01 2019-04-04 노파르티스 아게 Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
EP3494139B1 (de) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
EP3523451A1 (de) 2016-10-06 2019-08-14 Genentech, Inc. Therapeutische und diagnostische verfahren für krebs
JP2019535250A (ja) 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
KR20190077103A (ko) 2016-11-21 2019-07-02 오비아이 파머 인코퍼레이티드 접합된 생물학적 분자, 제약 조성물 및 방법
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
AU2018250875A1 (en) 2017-04-13 2019-10-03 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
AU2018304458B2 (en) 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
MX2020000903A (es) 2017-08-11 2020-07-22 Genentech Inc Anticuerpos anti-cd8 y usos de los mismos.
EP3679159A1 (de) 2017-09-08 2020-07-15 H. Hoffnabb-La Roche Ag Diagnose- und therapieverfahren für krebs
MX2020004567A (es) 2017-11-06 2020-08-13 Genentech Inc Metodos diagnosticos y terapeuticos para el cancer.
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
AU2019275404A1 (en) 2018-05-21 2020-12-03 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
BR112020026384A2 (pt) 2018-06-23 2021-03-30 Genentech, Inc. Métodos para tratar um indivíduo com câncer de pulmão e para tratar um indivíduo com câncer de pulmão de pequenas células, kits, anticorpo anti-pd-l1 e composição
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
CA3104147A1 (en) 2018-07-18 2020-01-23 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020051099A1 (en) 2018-09-03 2020-03-12 Genentech, Inc. Carboxamide and sulfonamide derivatives useful as tead modulators
WO2020061060A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
EP4249917A3 (de) 2018-09-21 2023-11-08 F. Hoffmann-La Roche AG Diagnosemethoden für dreifach-negativen brustkrebs
EP3867646A1 (de) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostische und therapeutische verfahren für sarkomatoiden nierenkrebs
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (de) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituierte pyrazolo[1,5-a]pyridin-verbindungen als inhibitoren von fgfr-tyrosinkinasen
CN113396230A (zh) 2019-02-08 2021-09-14 豪夫迈·罗氏有限公司 癌症的诊断和治疗方法
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
JP2022521773A (ja) 2019-02-27 2022-04-12 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
US20220146495A1 (en) 2019-02-27 2022-05-12 Epiaxis Therapeutics Pty Ltd Methods and agents for assessing t-cell function and predicting response to therapy
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
EP3962947A2 (de) 2019-05-03 2022-03-09 F. Hoffmann-La Roche AG Verfahren zur behandlung von krebs mit einem anti-pd-l1-antikörper
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
TW202124439A (zh) 2019-09-04 2021-07-01 美商建南德克公司 Ｃｄ８結合劑及其用途
JP2022548978A (ja) 2019-09-27 2022-11-22 ジェネンテック， インコーポレイテッド 薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
CN114728936A (zh) 2019-10-29 2022-07-08 豪夫迈·罗氏有限公司 用于治疗癌症的双功能化合物
MX2022005400A (es) 2019-11-06 2022-05-24 Genentech Inc Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
CA3155989A1 (en) 2019-11-13 2021-05-20 Jason Robert ZBIEG Therapeutic compounds and methods of use
AU2020403145A1 (en) 2019-12-13 2022-07-07 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
AU2020408562A1 (en) 2019-12-20 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
EP3915576A1 (de) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Für p95her2 spezifische chimäre antigenrezeptoren und deren verwendung
KR20230025691A (ko) 2020-06-16 2023-02-22 제넨테크, 인크. 삼중 음성 유방암을 치료하기 위한 방법과 조성물
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CN115843335A (zh) 2020-06-30 2023-03-24 国家医疗保健研究所 用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法
JP2023531305A (ja) 2020-06-30 2023-07-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法後の固形癌患者の再発及び／又は死亡のリスクを予測するための方法。
EP3939999A1 (de) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Antikörper zur neutralisierung der interleukin-11-rezeptor-alpha-unterheinheit (il11ra) und verwendungen davon
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
JP2023536602A (ja) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
MX2023003338A (es) 2020-09-23 2023-06-14 Erasca Inc Piridonas y pirimidonas tricíclicas.
CA3193952A1 (en) 2020-10-05 2022-04-14 Bernard Martin Fine Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
AU2022221124A1 (en) 2021-02-12 2023-08-03 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
KR20240026948A (ko) 2021-05-25 2024-02-29 에라스카, 아이엔씨. 황 함유 헤테로방향족 트리사이클릭 kras 억제제
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
IL309048A (en) 2021-06-22 2024-02-01 Regeneron Pharma Anti-EGFRVIII drug antibody conjugates and uses thereof
TW202321261A (zh) 2021-08-10 2023-06-01 美商伊瑞斯卡公司 選擇性ｋｒａｓ抑制劑
TW202340212A (zh) 2021-11-24 2023-10-16 美商建南德克公司 治療性化合物及其使用方法
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
EP4253418A1 (de) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immunzellen, die chimäre antigenrezeptoren exprimieren, und bispezifische antikörper und verwendungen davon
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628986B2 (en) 2003-06-27 2009-12-08 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7736644B2 (en) 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9062113B2 (en) 2003-06-27 2015-06-23 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9073998B2 (en) 2003-06-27 2015-07-07 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9085624B2 (en) 2003-06-27 2015-07-21 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9096672B2 (en) 2003-06-27 2015-08-04 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US10118968B2 (en) 2003-06-27 2018-11-06 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US10508153B2 (en) 2003-06-27 2019-12-17 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US11492411B2 (en) 2003-06-27 2022-11-08 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Also Published As

Publication number Publication date
JPH05500158A (ja) 1993-01-21
EP0491007A1 (de) 1992-06-24
AU6542790A (en) 1991-04-08
US5814317A (en) 1998-09-29
WO1991003489A1 (en) 1991-03-21
EP0491007B1 (de) 1996-03-13
ATE135373T1 (de) 1996-03-15
CA2066428C (en) 2000-11-28
US5212290A (en) 1993-05-18
DE69025946D1 (de) 1996-04-18
US5401828A (en) 1995-03-28
AU639726B2 (en) 1993-08-05
JP2975679B2 (ja) 1999-11-10
US5710010A (en) 1998-01-20

Similar Documents

Publication Publication Date Title
DE69025946D1 (de) Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
Fujimura et al. Mutation near the polyoma DNA replication origin permits productive infection of F9 embryonal carcinoma cells
van den Elsen et al. The relationship between region E1a and E1b of human adenoviruses in cell transformation
Pershouse et al. Analysis of the functional role of chromosome 10 loss in human glioblastomas
Kozbor et al. Amplification of the c-myc oncogene in one of five human breast carcinoma cell lines
Rachkovsky et al. Melanoma× macrophage hybrids with enhanced metastatic potential
Linney et al. DNA fragments from F9 PyEC mutants increase expression of heterologous genes in transfected F9 cells
US5650285A (en) Human CRIPTO-related gene and method of measuring CR-3
Steck et al. Two tumor suppressive loci on chromosome 10 involved in human glioblastomas
Bardi et al. Deletion of 1p36 as a primary chromosomal aberration in intestinal tumorigenesis
Asselin et al. Sequences from polyomavirus and simian virus 40 large T genes capable of immortalizing primary rat embryo fibroblasts
Minoletti et al. The two genes generating RET/PTC3 are localized in chromosomal band 10q11. 2
Galanti et al. Characterization and biological activity of cloned simian virus 40 DNA fragments.
Asselin et al. Role of the three polyoma virus early proteins in tumorigenesis
Phillips et al. Isolation of gene associated with high metastatic potential in rat mammary adenocarcinomas
Westbrook et al. Chromosomal localization and characterization of c-abl in the t (6; 9) of acute nonlymphocytic leukemia.
Chua et al. Tumor necrosis factor-α induces mRNA for collagenase and TIMP in human skin fibroblasts
Anderson et al. Simian virus 40-specific polypeptides in AD2+ ND1-and Ad2+ ND4-infected cells
Suzuki et al. The human IL-2 receptor gene contains a positive regulatory element that functions in cultured cells and cell-free extracts.
Kakati et al. Banding patterns of Chinese hamster chromosomes
Jones et al. Amplification and expression of the TGF-α, EGF receptor and c-myc genes in four human oesophageal squamous cell carcinoma lines
Mizuki et al. Amplification of c-Ki-ras gene and aberrant expression of c-myc in WI-38 cells transformed invitro by γ-irradiation
Deschamps et al. Proto-oncogene fos is expressed during development, differentiation, and growth
SILLETTI et al. Autocrine motility factor-receptor in human bladder-carcinoma-gene-expression, loss of cell-contact regulation and chromosomal mapping
Alsop et al. Distribution of breakpoints on chromosome 18 in breast, colorectal, and pancreatic carcinoma cell lines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition